1 min read

ID: 782667

Short Link: https://gregory-ms.com/articles/782667/

Discovery Date: 27 July 2022, 17:45:06 UTC

Published Date: 2022-07-27 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35894247/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220727134505&v=2.17.7

Manual Selection: none

Machine Learning Gaussian Naive Bayes Model: true

Abstract

CONCLUSION: Relapse during or prior to the treatment gap, and younger age, are of prognostic relevance in the year after switching to cladribine. Switching from NTZ is also independently associated with greater relapse hazard.

Noun Phrases in Title

  • Prediction
  • relapse activity
  • cladribine
  • multiple sclerosis
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.